Amicus Therapeutics (NASDAQ:FOLD) Given “Equal Weight” Rating at Morgan Stanley

Amicus Therapeutics (NASDAQ:FOLD – Get Free Report)‘s stock had its “equal weight” rating reaffirmed by research analysts at Morgan Stanley in a report released on Friday,Benzinga reports. They currently have a $12.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $17.00. Morgan Stanley’s target price indicates a potential upside […]

Leave a Reply

Your email address will not be published.

Previous post Thursday’s high school scores and highlights
Next post Cadence Design Systems (NASDAQ:CDNS) Given New $350.00 Price Target at Mizuho